Markets:

Overview

News

Currencies

International

Treasuries

Bristol-Myers Squibb (NY:BMY)

55.90 -0.82 (-1.45%)

Official Closing Price Updated: 7:00 PM EST, Jan 8, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Bristol-Myers Squibb

< Previous 1 2

...

6 7 8 9 10 11 12 13 14

...

85 86 Next >

Why Bristol-Myers Squibb (BMY) Shares Are Sliding Today

July 11, 2025

Shares of biopharmaceutical company Bristol Myers Squibb (NYSE:BMY) fell 3.5% in the afternoon session after a cautious analyst note from UBS highlighting significant upcoming expenses and other...

Via StockStory

Top S&P500 movers in Friday's session ↗

July 11, 2025

Let's have a look at what is happening on the US markets one hour before the close of the markets on Friday. Below you can find the top S&P500 gainers and losers in today's session.

Via Chartmill

What's going on in today's session: S&P500 movers ↗

July 11, 2025

Uncover the latest developments among S&P500 stocks in today's session. Stay tuned to the S&P500 index's top gainers and losers on Friday.

Via Chartmill

Price Over Earnings Overview: Bristol-Myers Squibb ↗

July 04, 2025

Via Benzinga

Why Is Nano-Cap MiNK Therapeutics Stock Gaining Over 400% On Friday? ↗

July 11, 2025

MiNK Therapeutics shares jumped as new clinical data show durable remission in testicular cancer and tumor reduction in gastric cancer using its iNKT cell therapy, agenT-797, in combination with...

Via Benzinga

What's going on in today's session: S&P500 gap up and gap down stocks ↗

July 11, 2025

Curious about the market action on Friday? Dive into the US markets to explore the gap up and gap down stocks in the S&P500 index during today's session.

Via Chartmill

Trump Threatens 200% Pharma Tariffs, But Analyst Says This Stock Is Immune And Expected To 'Benefit' From Levies ↗

July 11, 2025

Donald Trump's proposed 200% tariffs can squeeze the profit margins of pharma companies, but LLY is poised to "benefit" except for the rest.

Via Benzinga

Topics Government World Trade

2 Top Stocks Down 16% and 17% This Year to Buy and Hold ↗

July 11, 2025

Via The Motley Fool

Topics Intellectual Property

Why Is AbbVie Stock Trading Higher On Thursday? ↗

July 10, 2025

AbbVie licensed IGI's trispecific myeloma drug ISB 2001 in a deal worth up to $1.925 billion following strong early-phase clinical data.

Via Benzinga

What Analysts Are Saying About Bristol-Myers Squibb Stock ↗

July 10, 2025

Via Benzinga

Warren Buffett's Quiet Dividend Play: 9 High-Yield Stocks Held By A Berkshire Subsidiary ↗

July 09, 2025

Warren Buffett is indirectly invested in high-dividend yield stocks via Berkshire Hathaway Inc.'s subsidiary New England Asset Management.

Via Benzinga

Branded Pharmaceuticals Stocks Q1 Recap: Benchmarking Merck (NYSE:MRK)

July 08, 2025

As the Q1 earnings season comes to a close, it’s time to take stock of this quarter’s best and worst performers in the branded pharmaceuticals industry, including Merck (NYSE:MRK) and its peers.

Via StockStory

Topics Artificial Intelligence Intellectual Property

Warren Buffett Owns 9 Ultra-High-Yield Dividend Stocks. Here's the Best of the Bunch. ↗

July 07, 2025

Via The Motley Fool

Topics ETFs Regulatory Compliance

AstraZeneca In $15B Talks For Drug That Could Upend Lung Cancer Treatment ↗

July 03, 2025

Via Benzinga

Is Pfizer Stock a Yield Trap? ↗

July 03, 2025

Via The Motley Fool

Topics Intellectual Property

10 Health Care Stocks With Whale Alerts In Today's Session ↗

July 02, 2025

Via Benzinga

3 Large-Cap Stocks Skating on Thin Ice

July 02, 2025

Large-cap stocks have the power to shape entire industries thanks to their size and widespread influence. With such vast footprints, however, finding new areas for growth is much harder than for...

Via StockStory

FDA Eases Access To Life-Saving Gene Therapies For Blood Cancers ↗

June 30, 2025

FDA lifts REMS for approved CAR-T therapies, easing hospital restrictions and signaling broader future access in oncology and autoimmune treatment.

Via Benzinga

BRISTOL-MYERS SQUIBB CO (NYSE:BMY) - A High-Yield Dividend Stock Worth Considering ↗

June 28, 2025

BRISTOL-MYERS SQUIBB (NYSE:BMY) offers a high 5.29% dividend yield, strong profitability, and a reasonable valuation, making it a compelling choice for dividend investors.

Via Chartmill

FDA Eases Rules For Bristol Myers' Cell Therapies For Blood Cancers ↗

June 27, 2025

FDA approved label changes for Breyanzi and Abecma, easing access by reducing monitoring rules and eliminating REMS safety program requirements.

Via Benzinga

U.S. Food and Drug Administration Approves Streamlined Patient Monitoring Requirements and Removal of REMS Programs within Bristol Myers Squibb’s Cell Therapy Labels

June 26, 2025

From Bristol Myers Squibb

Via Business Wire

Why New Incyte CEO Bill Meury Is Stoking Investors' M&A Hopes ↗

June 26, 2025

Bill Meury will take the place of Herve Hoppenot, who is retiring after 11 years at Incyte's helm.

Via Investor's Business Daily

Bristol Myers Faces Scrutiny For Allegedly Rigging Market On $2B Cancer Drug ↗

June 25, 2025

Bristol Myers and Celgene are being sued in an antitrust suit, alleging they used fraud, sham litigation, and reverse payments to delay cheaper generics of Pomalyst.

Via Benzinga

Topics Fraud Lawsuit

BRISTOL-MYERS SQUIBB CO (NYSE:BMY) – A Potentially Undervalued Stock Worth Considering ↗

June 23, 2025

BRISTOL-MYERS SQUIBB CO (NYSE:BMY) offers strong profitability, a high dividend yield, and an attractive valuation, making it a potential pick for value investors.

Via Chartmill

Q1 Rundown: Royalty Pharma (NASDAQ:RPRX) Vs Other Branded Pharmaceuticals Stocks

June 18, 2025

Quarterly earnings results are a good time to check in on a company’s progress, especially compared to its peers in the same sector. Today we are looking at Royalty Pharma (NASDAQ:RPRX) and the best...

Via StockStory

Topics Artificial Intelligence Intellectual Property

Q1 Earnings Outperformers: Eli Lilly (NYSE:LLY) And The Rest Of The Branded Pharmaceuticals Stocks

June 18, 2025

As the craze of earnings season draws to a close, here’s a look back at some of the most exciting (and some less so) results from Q1. Today, we are looking at branded pharmaceuticals stocks, starting...

Via StockStory

Topics Artificial Intelligence Intellectual Property

Bristol Myers Squibb Announces Dividend

June 17, 2025

From Bristol Myers Squibb

Via Business Wire

Bristol Myers’ Cancer Drug Data Fuels Retail Buzz, But Bearish Sentiment Lingers ↗

June 16, 2025

The new data showed that its lymphoma therapy, Breyanzi, delivered a 95.5% response rate and strong 24-month survival outcomes in a Phase 2 trial.

Via Stocktwits

Top S&P500 movers in Monday's session ↗

June 16, 2025

Let's have a look at the top S&P500 gainers and losers one hour before the close of the markets of today's session.

Via Chartmill

Bristol Myers Squibb Presents First Data from the Marginal Zone Lymphoma Cohort of the Transcend FL Trial Demonstrating Deep and Durable Responses with Breyanzi (lisocabtagene maraleucel)

June 16, 2025

From Bristol Myers Squibb

Via Business Wire

< Previous 1 2

...

6 7 8 9 10 11 12 13 14

...

85 86 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.